Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name:	Name:
Ward:	NHI:
/alganciclovir	
INITIATION – Transplant cytomegalovirus prophylaxis Re-assessment required after 3 months Prerequisites (tick box where appropriate)  Patient has undergone a solid organ transplant and requires valga	nciclovir for CMV prophylaxis
CONTINUATION – Transplant cytomegalovirus prophylaxis Re-assessment required after 3 months  Prerequisites (tick boxes where appropriate)	
CMV prophylaxis  and  Patient is to receive a maximum of 90 days of valgance	ceived anti-thymocyte globulin and requires valganciclovir therapy for iclovir prophylaxis following anti-thymocyte globulin
Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy for CMV prophylaxis  and Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone	
INITIATION – Lung transplant cytomegalovirus prophylaxis Re-assessment required after 12 months  Prerequisites (tick boxes where appropriate)  O Prescribed by, or recommended by a relevant specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.  and	
Patient has undergone a lung transplant  The donor was cytomegalovirus positive and the patie  The recipient is cytomegalovirus positive  and  Patient has a high risk of CMV disease	nt is cytomegalovirus negative
INITIATION – Cytomegalovirus in immunocompromised patients Prerequisites (tick boxes where appropriate)	
Patient is immunocompromised  O Patient has cytomegalovirus syndrome or tissue invas or O Patient has rapidly rising plasma CMV DNA in absence or O Patient has cytomegalovirus retinitis	

I confirm that the above details are correct:

Signed: ...... Date: .....